

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived human IL-15R alpha protein		
	Human IL-15R alpha (Ile31-Thr205) Accession # Q13261.1	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus
N-terminal Sequence	Ile31		
Analysis			
Structure / Form	Disulfide-linked homodimer, biotinylated via Avi-tag		
Predicted Molecular Mass	47 kDa		



SPECIFICATIONS

SDS-PAGE	70-80 kDa, under reducing conditions
Activity	The biotin to protein ratio is greater than 0.7 as determined by the HABA assay. Measured by its binding ability in a functional ELISA. When Biotinylated Recombinant Human IL-15R alpha Fc Chimera Avi-tag (Catalog # AVI7194) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human IL-15 (Catalog # 247-ILB) binds with an ED ₅₀ of 0.02-0.16 ng/mL.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 400 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Interleukin 15 Receptor alpha (IL-15 R alpha), also known as CD215, is a widely expressed 60-kDa transmembrane glycoprotein that plays an important role in the homeostasis and activation of NK cells and CD8+ memory T cells and participates in the development and function of many other hematopoietic cell types and non-immune cell types (1-3). Mature human IL-15 R alpha consists of a 175 amino acid (aa) extracellular domain (ECD) containing one N-linked glycosylation site, a 23 aa transmembrane segment, and a 39 aa cytoplasmic tail (4). Within the ECD, human IL-15 R alpha shares approximately 60% aa sequence identity with mouse and rat IL-15 R alpha. Alternate splicing of human IL-15 R alpha generates additional isoforms with variable length deletions in the ECD and/or substitutions in the cytoplasmic domain (4, 5). IL-15 R alpha binds to Interleukin-15 with high affinity (6). IL-15 additionally interacts with lower affinity to a complex of IL-2 R beta and the common gamma chain (gamma c) which are also subunits of the IL-2 receptor complex (7, 8). The use of shared receptor components contributes to the overlapping biological effects of IL-15 and IL-2. The dominant mechanism of IL-15 action is known as transpresentation in which IL-15/IL-15 R alpha complexes are expressed on the surface of one cell and interact with complexes of IL-2 R beta / gamma c on adjacent cells (9). This enables cells to respond to IL-15 even if they do not express IL-15 R alpha (10-12). IL-15/IL-15 R alpha complexes can transmit reverse signaling that promotes cellular adhesion, tyrosine phosphorylation of intracellular proteins, and cytokine secretion by the IL-15/IL-15 R alpha expressing cells (13, 14). Shed soluble forms of IL-15 R alpha retain the ability to bind tightly to IL-15 and can inhibit IL-15 bioactivity (6, 15, 16). Our Avi-tag Biotinylated Recombinant Human IL-15 R alpha features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References:

1. Ma, A. *et al.* (2006) *Annu. Rev. Immunol.* **24**:657.
2. Di Sabatino, A. *et al.* (2011) *Cytokine Growth Factor Rev.* **22**:19.
3. Budagian, V. *et al.* (2006) *Cytokine Growth Factor Rev.* **17**:259.
4. Anderson, D.M. *et al.* (1995) *J. Biol. Chem.* **270**:29862.
5. Dubois, S. *et al.* (1999) *J. Biol. Chem.* **274**:26978.
6. Giri, J.G. *et al.* (1995) *EMBO* **14**:3654.
7. Grabstein, K. *et al.* (1994) *Science* **264**:965.
8. Giri, J. *et al.* (1994) *EMBO J.* **13**:2822.
9. Stonier, S.W. and K.S. Schluns (2010) *Immunol. Lett.* **127**:85.
10. Duitman, E.H. *et al.* (2008) *Mol. Cell. Biol.* **28**:4851.
11. Dubois, S. *et al.* (2002) *Immunity* **17**:537.
12. Burkett, P.R. *et al.* (2004) *J. Exp. Med.* **200**:825.
13. Budagian, V. *et al.* (2004) *J. Biol. Chem.* **279**:42192.
14. Neely, G.G. *et al.* (2004) *J. Immunol.* **172**:4225.
15. Budagian, V. *et al.* (2004) *J. Biol. Chem.* **279**:40368.
16. Mortier, E. *et al.* (2004) *J. Immunol.* **173**:1681.